fig5

Figure 5. Serum oxLDL levels were increased in ALS compared to healthy controls. When fast progressing ALS patients were compared with slowly progressing patients, only fast progressors differed from controls. Slowly progressing patients did not differ from controls (**P < 0.001; n.s.= not significant). Serum HNE levels were also significantly different from controls (*P < 0.05), but only fast progressors differed from controls (**P < 0.01). Fast vs. slow progression was based upon changes of > 1.5 points vs. < 1.5 points on our AALS clinical scale^[45] (Modified from Figure 1, Ref. 32^[32]). ALS: Amyotrophic lateral sclerosis; HNE: 4-hydroxynonenal.